Endothelins: Their current status and future prospects

International Journal of Pharmaceutical Sciences Review and Research

Volumn 23, Issue 2, 2013, Pages 94-97

  Parida, Amrita ^a   Nayak, Veena ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Endothelin converting enzyme inhibitors; Endothelin receptor blockers; Endothelins

Indexed keywords

ALDOSTERONE; AMBRISENTAN; ATRASENTAN; BOSENTAN; CLAZOSENTAN; DARUSENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; MACITENTAN; MEMBRANE METALLOENDOPEPTIDASE; SITAXSENTAN; TEZOSENTAN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GLAUCOMA; HEADACHE; HUMAN; LIVER TOXICITY; MITOGENESIS; NEOPLASM; NOSE OBSTRUCTION; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; REVIEW; TRABECULAR MESHWORK; VASOCONSTRICTION;

EID: 84890453036     PISSN: 0976044X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Benigni A, Remuzzi G, Endothelin antagonists, The Lancet 353, 1999, 133-38.
2. Barton M, Yanagisawa M, Endothelins: 20 years from discovery to therapy, Can J PhysiolPharmacol, 86, 2008, 485-498.
3. Yanagisawa M, Kurihara H, Kimura S, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T, A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, 332, 1988, 411-415.
4. Luscher TF, Barton M, Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs, Circulation, 102, 2000, 2434-2440.
5. Rich S, McLaughlin VV, Endothelin receptor blockers in cardiovascular disease, Circulation, 108, 2003, 2184-2190.
6. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y, Kinoshita M, Comparison of the Effects of Selective Endothelin ETA and ETBReceptor Antagonists in Congestive Heart Failure, JACC,30(5), 1997, 1385-92.
7. Kirchengast M, Luz M, Endothelin receptor antagoinsts: clinical realities and future directions, J Cardiovasc Pharmacol, 45, 2005,182-191.
8. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacquis-Silva MC, Canani LH, Gross JL, Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus, Diabetes Res ClinPract, 80, 2008, 299-304.
9. Bhattacharya I, Ullrich A, Endothelin-1 inhibits adipogenisis: role of phosphorylation of Akt and ERK1/2, FEBS Lett 580, 2006, 5765-5771.
10. Grant K, Loizidou M, Taylor I, Endothelin-1: a multifunctional molecule in cancer, British journal of cancer, 88, 2003, 163-166.
11. Laurent S, Schlaich M, Esler M, Hypertension: New drugs, procedures, and devices for hypertension, Lancet, 380, 2012, 591-600.
12. Mellin V, Jeng AY, Monteil C, Renet S, Henry JP, Thuillez C, Mulder P, Triple ACE-ECE-NEP Inhibition in Heart Failure: AComparison With ACE and Dual ECE-NEP Inhibition, J CardiovascPharmacol, 46, 2005, 390-397.
13. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch BD, Roux S, Rainisio M, Bodin F, Rubin LJ, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study, The Lancet, 358, 2001, 1119-23.
14. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberget M, Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study, Circulation, 114, 2006, 48-54.
15. Pfizer. Pfizer Stops Clinical Trials of Thelin and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety. December 10, 2010. Available at: http://pfizer.mediaroom.com/index.php?s=5149&item=22387. Accessed September 2013.
16. Frampton JE, Ambrisentan, Am J Cardiovasc Drugs, 11(4), 2011,215-26.
17. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Nowbakht P, Roux S, Kassell N, Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke, 43(6), 2012, 1463-9.
18. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators, Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS), Am Heart J, 150(1),2005, 46-53.
19. Cosenzi A. Enrasentan, an antagonist of endothelin receptors, Cardiovasc Drug Rev,21, 2003, 1-16.
20. Liang F, Glascock CB, Schafer DL, Sandoval J, Cable L, Melvin L Jr, Hartman JC, Pitts KR, Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries, Can J PhysiolPharmacol, 88(8),2010, 840-9.
21. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA Jansa P, Jing ZC, Brun FL, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension, N Engl J Med, 369, 2013, 809-818.
22. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk PJ, Twardowski PJ, Veldhuizen PJV, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM, Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial, The Lancet Oncology, 14, 2013, 893-900.